The Cambridge Prognostic Groups for improved prediction of disease mortality at diagnosis in primary non-metastatic prostate cancer: a validation study

  title={The Cambridge Prognostic Groups for improved prediction of disease mortality at diagnosis in primary non-metastatic prostate cancer: a validation study},
  author={Vincent J. Gnanapragasam and Ola Bratt and Kenneth Muir and L. S. Lee and H. H. Huang and Paer Stattin and Artitaya Lophatananon},
  journal={BMC Medicine},
BackgroundThe purpose of this study is to validate a new five-tiered prognostic classification system to better discriminate cancer-specific mortality in men diagnosed with primary non-metastatic prostate cancer.MethodsWe applied a recently described five-strata model, the Cambridge Prognostic Groups (CPGs 1-5), in two international cohorts and tested prognostic performance against the current standard three-strata classification of low-, intermediate- or high-risk disease. Diagnostic clinico… 

Risk stratification for prostate cancer management: value of the Cambridge Prognostic Group classification for assessing treatment allocation

Background The five-tiered Cambridge Prognostic Group (CPG) classification is a better predictor of prostate cancer-specific mortality than the traditional three-tiered classification (low,

Population-Based Comparison of Different Risk Stratification Systems Among Prostate Cancer Patients

The NCCN-g and AUA-g risk stratification systems perform better in discriminating PCSM compared to the EAU-g system, and it is recommended to use NCCn-g to evaluate risk groups for prostate cancer patients and then provide more appropriate corresponding treatment recommendations.

Individual prognosis at diagnosis in nonmetastatic prostate cancer: Development and external validation of the PREDICT Prostate multivariable model

An individualised prognostic model that contextualises PCa-specific mortality (PCSM) against other cause mortality, and estimates the impact of treatment on survival, and is the first to the authors' knowledge that models potential treatment benefits on overall survival.

Models predicting survival to guide treatment decision-making in newly diagnosed primary non-metastatic prostate cancer: a systematic review

Few long-term prognostic models exist to inform decision-making at diagnosis of non-metastatic prostate cancer, and improved models are required to inform management and avoid undertreatment and overtreatment.

Discovery of PTN as a serum-based biomarker of pro-metastatic prostate cancer

Findings suggest that PTN may represent a novel biomarker for the presence of poor prognosis local disease with the potential to metastasise warranting further investigation.

Comparison of the treatment of men with prostate cancer between the US and England: an international population-based study

Men in the US were more likely to receive radical local treatment across all prognostic groups compared to men in England, raising potential over-treatment concerns for low-risk disease (CPG1-5) in theUS and under-treatment of clinically significant disease in England.

Clinical utility and cost modelling of the phi test to triage referrals into image-based diagnostic services for suspected prostate cancer: the PRIM (Phi to RefIne Mri) study

Phi as a triaging test may be an effective way to reduce mpMRI and biopsies without compromising detection of significant prostate cancers.

MRI-derived PRECISE scores for predicting pathologically-confirmed radiological progression in prostate cancer patients on active surveillance

The PRECISE scoring system showed good overall performance, and the high NPV may help limit the number of follow-up biopsies required in patients on active surveillance, which could reduce the need for re-biopsy during active surveillance.



Improving Clinical Risk Stratification at Diagnosis in Primary Prostate Cancer: A Prognostic Modelling Study

A new five-stratum risk stratification system based on the number of individual risk factors and incorporating the new ISUP prognostic score was developed and tested, demonstrating improved prognostic performance.

Successful external validation of a model to predict other cause mortality in localized prostate cancer

A new life expectancy prediction model for other cause mortality in localized prostate cancer patients that could aid clinician’s initial treatment decisions at the point of care is created and externally validated.

Risk Group and Death From Prostate Cancer: Implications for Active Surveillance in Men With Favorable Intermediate-Risk Prostate Cancer.

The results provide evidence to support AS as an initial approach for men with favorable intermediate-risk PC and similarly low estimates of PCSM and ACM during the first decade following brachytherapy.

A novel DNA methylation score accurately predicts death from prostate cancer in men with low to intermediate clinical risk factors

The derived methylation score is a strong predictor of aggressive prostate cancer that could have an important role in directing the management of patients with low-to-intermediate risk disease.

Proportion and characteristics of men with unknown risk category in the National Prostate Cancer Register of Sweden

Men with unknown risk category were rare in NPCR but distinctly different from other men in NPCr in many aspects including higher comorbidity and lower Pca mortality.

Definition and Validation of "Favorable High-Risk Prostate Cancer": Implications for Personalizing Treatment of Radiation-Managed Patients.

The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy.

The UCSF-CAPRA score is a straightforward yet powerful preoperative risk assessment tool which would be a strong predictor of outcome across various levels of risk and which could be easily applied and intuitively understood.

Trends and Outcome from Radical Therapy for Primary Non-Metastatic Prostate Cancer in a UK Population

Significant shifts in non-metastatic prostate cancer management over the last decade are identified, with low-risk disease now primarily managed by CM while high- risk disease is increasingly treated radically.

Incorporating multiparametric MRI staging and the new histological Grade Group system improves risk-stratified detection of bone metastasis in prostate cancer

Incorporating the new Grade Group system and mpMRI staging more accurately identified bone metastatic risk and suggests men with Grade Group ⩽2 and/or without radiological T3 disease could safely avoid routine bone staging.